Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields

Amid market turbulence, three high-yielding healthcare stocks—Medtronic (MDT), AbbVie (ABBV), and Premier (PINC)—have recently garnered updated analyst ratings and price target increases. Medtronic and AbbVie notably received maintained 'Buy' or 'Overweight' ratings with raised price targets from multiple analysts, coinciding with Medtronic's €1.5 billion senior notes pricing and AbbVie's settlement of generic litigation for upadacitinib. Premier also saw increased price targets, though ratings remained 'Neutral,' following the appointment of a new President of Supply Chain Services.

Analysis

In a market environment favoring defensive assets, three high-yield healthcare stocks exhibit divergent analyst outlooks despite all receiving recent price target increases. AbbVie (ABBV) emerges with the most bullish sentiment, evidenced by maintained 'Overweight' ratings from JP Morgan and Wells Fargo and substantial price target boosts to $235 and $260, respectively. This optimism is likely reinforced by the recent settlement of litigation concerning generic versions of upadacitinib, removing a key overhang and supporting its 3.03% dividend yield. Similarly, Medtronic (MDT) garnered continued 'Buy' ratings and raised price targets from Argus and Citigroup, coupled with a successful €1.5 billion senior notes pricing that demonstrates strong access to capital markets. In contrast, while Premier (PINC) offers the highest dividend yield of the group at 3.18% and saw its price targets increased, analysts at UBS and Baird maintained 'Neutral' ratings. This suggests a more cautious stance on the company's near-term prospects, even following the appointment of a new President of Supply Chain Services.

Key Decisions for Investors

• Given the strong 'Overweight' ratings, substantial price target increases, and the positive resolution of key litigation, investors could view AbbVie as a compelling opportunity for both capital growth and income, supported by its 3.03% dividend yield.
• Medtronic's consistent 'Buy' ratings and successful debt issuance position it as a stable choice for income-focused investors, though the more moderate price target increases suggest steady growth potential rather than significant near-term upside.
• Despite Premier having the highest dividend yield at 3.18%, the 'Neutral' analyst ratings warrant a cautious stance, and investors may want to monitor for tangible impacts from the new supply chain leadership before initiating or adding to positions.